
|Articles|October 15, 2002
Head-to-head trial: Phase III study tests options for wet AMD
Fort Worth, TX-Alcon Research Ltd. is enrolling about 500 patients in a phase III study to compare the effects of anecortave acetate versus verteporfin (Visudyne, Novartis) photodynamic therapy for the treatment of wet age-related macular degeneration.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement




























